Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Research & Development (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Research & Development for 16 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 0.85% to $6.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.8 million, a 1.87% decrease, with the full-year FY2025 number at $25.8 million, up 0.88% from a year prior.
  • Research & Development was $6.5 million for Q4 2025 at Anika Therapeutics, down from $6.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $8.9 million in Q2 2023 to a low of -$3.3 million in Q4 2023.
  • A 5-year average of $6.0 million and a median of $6.5 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 135.2% in 2022, then soared 294.7% in 2024.
  • Anika Therapeutics' Research & Development stood at $6.0 million in 2021, then tumbled by 135.2% to -$2.1 million in 2022, then crashed by 58.24% to -$3.3 million in 2023, then skyrocketed by 294.7% to $6.5 million in 2024, then decreased by 0.85% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Research & Development are $6.5 million (Q4 2025), $6.9 million (Q3 2025), and $6.3 million (Q2 2025).